Abstract Number: 2501 • ACR Convergence 2023
Selection of Indicators Reporting Response Rate in Pharmaceutical Trials for Systemic Lupus Erythematosus: Preference and Relative Sensitivity
Background/Purpose: Systemic lupus erythematosus (SLE) is a common multisystem autoimmune disease with chronic inflammation. Many efficacy evaluation indicators of randomized clinical trials (RCTs) for SLE…Abstract Number: 2537 • ACR Convergence 2023
Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Background/Purpose: Biologic and targeted synthetic DMARDs (b/tsDMARDs) are widely used to treat patients with various autoimmune inflammatory diseases (ARD). Use of a b/tsDMARD in patients…Abstract Number: 0331 • ACR Convergence 2023
Assessment of Patient Adherence to “Sick Day Rules”: A Cross-sectional Study of Rheumatology Outpatients Prescribed Immunosuppressive Medications
Background/Purpose: Rheumatology outpatients receiving immunosuppressive medications (IS) inevitably develop acute infections. Expert guidance, in accordance with usual clinical practice, recommends counseling patients on “sick day…Abstract Number: 0482 • ACR Convergence 2023
Preference and Relative Sensitivity of Indicators Reporting Response Rate in Pharmaceutical Trials of Psoriasis and Psoriatic Arthritis
Background/Purpose: Numerous indicators have been proposed to evaluate the efficacy for randomized clinical trials (RCTs) of psoriasis (Pso) and psoriatic arthritis (PsA), but the comparability…Abstract Number: 1083 • ACR Convergence 2023
A Patient-Centered Approach to Increase Herpes Zoster Vaccination in Patients on Janus Kinase Inhibitors: A Fellowship Quality Improvement Initiative
Background/Purpose: People with systemic rheumatologic diseases are more susceptible to herpes zoster (HZ) infection and its complications due to their underlying diseases and the medications…Abstract Number: 1085 • ACR Convergence 2023
Utilizing a Maintenance of Certification (MOC) Part 4 Quality Improvement Project to Improve Data Completeness in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: Minimizing missing data in research registries is a universal challenge. Enrolling patients into a research registry with poor data quality is wasteful and potentially…Abstract Number: 1088 • ACR Convergence 2023
Improving JIA Outcomes Assessments in a Large Pediatric Rheumatology Practice: A Fellow Quality Improvement Project
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease that can result in long-term joint damage if inadequately treated. Collecting validated outcomes data at…Abstract Number: 1090 • ACR Convergence 2023
Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center
Background/Purpose: We embedded a clinical pharmacist into our university rheumatology clinics beginning in June 2022 to improve patient experience and reduce provider burden based on…Abstract Number: 1897 • ACR Convergence 2023
In Pursuit of Excellence: Improving Systemic Sclerosis Quality of Care
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease with significant morbidity and mortality. Quality indicators (QIs) for SSc care, previously published, are essential tools…Abstract Number: 1899 • ACR Convergence 2023
Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States
Background/Purpose: Collaborating with the Centers for Disease Control and Prevention (CDC), the ACR has developed new quality measures for lupus clinical care, including clinical and…Abstract Number: 1908 • ACR Convergence 2023
Clinic Protocol Boosts Blood Pressure Confirmatory Readings and Accuracy in an Academic Medical Center
Background/Purpose: Hypertension is the most common modifiable risk factor for cardiovascular diseases among all adults. Studies have shown that single blood pressure (BP) measurements vary…Abstract Number: 111 • 2023 Pediatric Rheumatology Symposium
Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center
Background/Purpose: Hypogammaglobulinemia is an under-recognized complication of B-cell targeted therapies (BCTT) in both autoimmune diseases (AID) and malignancy. Hypogammaglobulinemia may be transient or persistent, and…Abstract Number: 131 • 2023 Pediatric Rheumatology Symposium
Improving Methotrexate Documentation in Electronic Health Records – a Quality Improvement Initiative
Background/Purpose: Prescribing methotrexate,is common practice in rheumatology. Appropriate medication counselling and documentation is important. In our province, as per thephysician regulatory body the College of…Abstract Number: 132 • 2023 Pediatric Rheumatology Symposium
Quality Improvement Lessons in a New Practice
Background/Purpose: Children with Juvenile Idiopathic Arthritis (JIA) have better disease outcomes with current medications available, yet there is variability in these outcomes. Quality improvement (QI)…Abstract Number: 1298 • ACR Convergence 2022
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a Learning Health Network designed to improve outcomes of care for children with juvenile idiopathic…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »